Leerink Partnrs Lowers Earnings Estimates for Bio-Techne

Bio-Techne Corp (NASDAQ:TECH - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2026 earnings estimates for Bio-Techne in a report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will earn $0.52 per share for the quarter, down from their prior estimate of $0.54. The consensus estimate for Bio-Techne's current full-year earnings is $1.67 per share.

Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.51 by $0.05. Bio-Techne had a net margin of 10.89% and a return on equity of 13.17%. The firm had revenue of $316.18 million during the quarter, compared to analyst estimates of $317.92 million. During the same quarter in the prior year, the business earned $0.48 earnings per share. Bio-Techne's revenue for the quarter was up 4.2% on a year-over-year basis.

Several other equities analysts have also commented on the stock. Wells Fargo & Company initiated coverage on shares of Bio-Techne in a research report on Friday, May 30th. They set an "overweight" rating and a $59.00 price objective for the company. Stifel Nicolaus reduced their price target on shares of Bio-Techne from $75.00 to $60.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. KeyCorp reissued a "sector weight" rating on shares of Bio-Techne in a research report on Wednesday, April 9th. Wall Street Zen downgraded shares of Bio-Techne from a "buy" rating to a "hold" rating in a research report on Sunday, June 8th. Finally, UBS Group cut their target price on shares of Bio-Techne from $95.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $70.00.

Bio-Techne Price Performance

TECH stock traded down $0.68 during trading on Friday, hitting $52.61. 299,677 shares of the company's stock traded hands, compared to its average volume of 1,474,365. Bio-Techne has a 52 week low of $46.01 and a 52 week high of $83.62. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.58 and a current ratio of 3.71. The business has a fifty day simple moving average of $50.48 and a 200 day simple moving average of $58.46. The stock has a market capitalization of $8.25 billion, a price-to-earnings ratio of 64.14, a P/E/G ratio of 2.46 and a beta of 1.39.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Monday, May 19th were paid a dividend of $0.08 per share. The ex-dividend date was Monday, May 19th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.61%. Bio-Techne's payout ratio is 39.02%.

Bio-Techne declared that its board has authorized a stock repurchase plan on Wednesday, May 7th that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to repurchase up to 6.5% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

Hedge Funds Weigh In On Bio-Techne

Several hedge funds have recently added to or reduced their stakes in TECH. Proficio Capital Partners LLC boosted its holdings in shares of Bio-Techne by 13.6% in the fourth quarter. Proficio Capital Partners LLC now owns 3,367 shares of the biotechnology company's stock valued at $243,000 after acquiring an additional 402 shares during the period. Sequoia Financial Advisors LLC increased its position in shares of Bio-Techne by 63.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 4,460 shares of the biotechnology company's stock valued at $321,000 after buying an additional 1,735 shares in the last quarter. Natixis Advisors LLC increased its position in Bio-Techne by 7.4% during the 4th quarter. Natixis Advisors LLC now owns 169,681 shares of the biotechnology company's stock worth $12,222,000 after purchasing an additional 11,625 shares in the last quarter. Cibc World Markets Corp increased its position in Bio-Techne by 17.0% during the 4th quarter. Cibc World Markets Corp now owns 25,032 shares of the biotechnology company's stock worth $1,803,000 after purchasing an additional 3,631 shares in the last quarter. Finally, Royal London Asset Management Ltd. increased its position in Bio-Techne by 17.8% during the 4th quarter. Royal London Asset Management Ltd. now owns 67,306 shares of the biotechnology company's stock worth $4,848,000 after purchasing an additional 10,170 shares in the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.